Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy?

Sarah C J Jorgensen¹, Lisa Burry^{1

2}, Christopher L Y Tse², Linda D Dresser^{2

3}

Affiliations

¹ Department of Pharmacy, Sinai Health System, Toronto, Ontario, Canada.
² Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
³ Antimicrobial Stewardship Program, University Health Network, Toronto, Ontario, Canada.

Comment

Sarah C J Jorgensen et al. Clin Infect Dis. 2021.

. 2021 Dec 6;73(11):e3978-e3979.

doi: 10.1093/cid/ciaa1208.

Sarah C J Jorgensen¹, Lisa Burry^{1

2}, Christopher L Y Tse², Linda D Dresser^{2

3}

¹ Department of Pharmacy, Sinai Health System, Toronto, Ontario, Canada.
² Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
³ Antimicrobial Stewardship Program, University Health Network, Toronto, Ontario, Canada.

No abstract available

Comment in

Response to Correspondence: Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy? Jorgensen et al.
Titanji BK, Farley MM, Schinazi RF, Marconi VC. Titanji BK, et al. Clin Infect Dis. 2021 Dec 6;73(11):e3980-e3981. doi: 10.1093/cid/ciaa1210. Clin Infect Dis. 2021. PMID: 32797226 Free PMC article. No abstract available.

Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019.
Titanji BK, Farley MM, Mehta A, Connor-Schuler R, Moanna A, Cribbs SK, O'Shea J, DeSilva K, Chan B, Edwards A, Gavegnano C, Schinazi RF, Marconi VC. Titanji BK, et al. Clin Infect Dis. 2021 Apr 8;72(7):1247-1250. doi: 10.1093/cid/ciaa879. Clin Infect Dis. 2021. PMID: 32597466 Free PMC article.